Follow Up Statement on Dexamethasone by the Minister of Health
On 16 June, I conveyed our excitement, as a Department, around the breakthrough research of the RECOVERY trial from Oxford University in Britain.
In this trial, they studied the therapeutic eﬀects of dexamethasone, an anti-inflammatory medicine well known in the clinical setting to manage inflammatory processes that are seen in clinical setting such as asthma, allergic reactions, auto-immune disease and brain swelling (oedema).
Dexamethasone was found to reduce mortality by one third in patients who required ventilatory support and by one fifth in patients who required non invasive supplementary oxy- gen.
This is a significant breakthrough in evidence based management of COVID-19. The study results are compelling because it was a randomized study that was able to recruit large numbers of participants (6425).
There is no other medicine that has shown this level of eﬃcacy against COVID-19 to date.
The study showed no benefit for those patients who did not require oxygen supplementation.
Since this announcement, we have looked into our own context and found that we are indeed in a favourable position.
Our health care workers are very familiar with dexamethasone, having used it for decades as a registered medicine in South Africa.
We are immediately able to oﬀer all patients that need intravenous dexamethasone- we have checked our stock and we currently have around 300 000 ampoules in the country.
This is one of those medicines where we do have excellent local capacity. There are three major suppliers of intravenous dexamethasone in the country. One of the companies manufactures the oral equivalent and supplies it all over the world and so we are able to negotiate the security of our own supply right here at home.
In fact, to have a South African enterprise be a manufacturer and supplier of a critical medicine, especially one that will prove to be lifesaving in the current global context, is a real departure from the norm and so South Africans can take pride in being one of the countries that will provide a solution to a global crisis.
Our Ministerial Advisory Committee on COVID-19 issued an advisory to recommend the use of dexamethasone (or an equivalent steroid like hydrocortisone or prednisolone) for all COVID-19 patients on ventilators or requiring non-invasive supplementary oxygen.
Dexamethasone is not recommended for asymptomatic patients or patients with symptoms who do not require oxygen.
This breakthrough is excellent news for us and we are especially fortunate that it came as we are preparing for our upcoming surge.
The strategy is easy to implement as the medicine is inexpensive, easy to transport, easy to administer and will not require too much additional training.
Whilst the MAC has made it clear their advisory is issued while awaiting the full study paper for closer assessment, we have learnt that leading clinicians in academic hospitals have been using the medicine and they are very excited that their anecdotal experiences have now been aﬃrmed by higher levels of evidence.
We therefore will be moving ahead to issue guidelines for the use of dexamethasone in all our facilities for desperately ill COVID-19 patients.
We are so pleased that we have the wherewithal to deliver quality, evidence based health care to those who need it the most.
As a nation, we see value in participating in clinical trials that comply with the highest ethi- cal standards. This ensures that we contribute to the body of knowledge and secure our access to therapeutics when they are ready for clinical application.